Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
800 participants
OBSERVATIONAL
2016-11-01
2021-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
NCT03187678
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
NCT00370214
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
NCT03492177
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
NCT00667823
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
NCT01389206
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group/Cohort Information
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients ≥ 18 years of age at time of Uptravi initiation, and
* Patients who initiate Uptravi:
* at enrollment, or
* less than or equal to 60 days prior to enrollment and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and dates and highest tolerated dose and dates)
Exclusion Criteria
* Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
* Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Actelion
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Actelion
Role: STUDY_DIRECTOR
Actelion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Alabama
Mobile, Alabama, United States
Pulmonary Associates
Phoenix, Arizona, United States
Cardioivascular Consultants, Ltd.
Phoenix, Arizona, United States
University of Arizona-Clinical Translational and Regenerative Medicine
Tucson, Arizona, United States
University of California San Diego
La Jolla, California, United States
University of Southern California
Los Angeles, California, United States
VA Greater Los Angeles Healthcare Center
Los Angeles, California, United States
UCSF Medical Center
San Francisco, California, United States
Santa Barbara Cottage Hospital
Santa Barbara, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA
Torrance, California, United States
University of Colorado
Aurora, Colorado, United States
National Jewish Health
Denver, Colorado, United States
Banner Health Research Institute
Greeley, Colorado, United States
Florida Lung Asthma and Sleep Specialists
Celebration, Florida, United States
Broward Pulmonary and Sleep
Fort Lauderdale, Florida, United States
University of Florida, HSC
Gainesville, Florida, United States
West Pasco Pulmonary Associates
Hudson, Florida, United States
University of Florida-Jacksonville College of Medicine
Jacksonville, Florida, United States
Central Florida Pulmonary Group
Orlando, Florida, United States
University of South Florida
Tampa, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
Wellstar Marietta Pulmonary Medicine
Marietta, Georgia, United States
University of Chicago Hospitals
Chicago, Illinois, United States
Indiana University Health
Indianapolis, Indiana, United States
St. Vincent Medical Group, Inc.
Indianapolis, Indiana, United States
CIC Associates
Clive, Iowa, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Norton Pulmonary Specialists
Louisville, Kentucky, United States
University of Louisville
Louisville, Kentucky, United States
LSU Health Sciences Center
New Orleans, Louisiana, United States
Oschner Clinic Foundation/Oschner Medical Center
New Orleans, Louisiana, United States
Chest Medicine Associates
South Portland, Maine, United States
University of Maryland
Baltimore, Maryland, United States
Tufts University Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Sparrow Clinical Research Institute
Lansing, Michigan, United States
William Beaumont Hospital
Troy, Michigan, United States
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Mercy Research, Mercy Hospital Saint Louis
St Louis, Missouri, United States
Somnos Clinical Research
Lincoln, Nebraska, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Newark Beth Israel Medical Center
Newark, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
Pulmonary Health Physicians, PC
Fayetteville, New York, United States
Winthrop University Hospital
Mineola, New York, United States
Northwell Health
New Hyde Park, New York, United States
Mount Sinai Hospital
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Weil Cornell Medicine
New York, New York, United States
Stony Brook University Medical Center
Stony Brook, New York, United States
University of North Carolina Hospitals at Chapel Hill
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
The Lindner Research Center at The Christ Hospital
Cincinnati, Ohio, United States
University of Cincinnati
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Southwest General Health Center
Middleburg Heights, Ohio, United States
Legacy Medical Group-Pulmonary and Sleep Clinic
Portland, Oregon, United States
Oregon Health & Science University
Portland, Oregon, United States
Doylestown Health Cardiology
Doylestown, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Temple University Hospital
Philadelphia, Pennsylvania, United States
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
York Hospital
York, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
AnMed Health Medical Center
Anderson, South Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor Scott and White Health
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
University of Texas, Houston Health Center
Houston, Texas, United States
Methodist Healthcare of San Antonio
San Antonio, Texas, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Inova Fairfax
Falls Church, Virginia, United States
Sentara Cardiovascular Research Institute
Norfolk, Virginia, United States
Providence Health & Services d/b/a/ Providence Sacred Heart Medical Center & Children's Hospital Providence Medical Research Center
Spokane, Washington, United States
Multicare Institute for Research & Innovation
Tacoma, Washington, United States
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
Medical College of Wisconsin/Froedtert Hospital
Milwaukee, Wisconsin, United States
Aurora Research Institute / Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
CardioPulmonary Research, PSC
Guaynabo, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim NH, Hemnes AR, Chakinala MM, Highland KB, Chin KM, McLaughlin V, Zhao C, Narayan V, Farber HW. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021 Apr;40(4):279-288. doi: 10.1016/j.healun.2021.01.006. Epub 2021 Jan 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-065A402
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.